The impact of new technologies on clinical decision-making in health care

December 16, 2015
9 a.m. Pacific, 12 noon Eastern, 5 p.m. UK, 6 p.m. Central Europe

Brought to you by the Science/AAAS Custom Publishing Office

Submit your questions now to the panelists by sending an e-mail to:

Please keep your questions short and to the point to give them the best chance of being asked. Questions will be put to the experts during the webinar.


Decision-making in the clinic has been revolutionized by high-throughput technologies for genomic/transcriptomic sequencing and proteome/metabolome analysis. Close collaborations between academia and health care have driven the implementation of frontline technologies and bioinformatics in clinical diagnostics. As a result, clinicians are able to make faster and better-informed assessments of a patient’s condition, allowing treatment to be personalized for maximum efficacy. These advances have also provided new opportunities to understand disease mechanisms and develop novel treatment strategies. In this webinar, our expert panel will demonstrate how both diagnosis and treatment can be improved and lives saved using next-generation genomic profiling and functional analyses.

The speakers will place special emphasis on:

  • Precision cancer medicine for solid tumors as well as leukemias
  • Monogenic disorders, such as inborn errors of metabolism (IEM)
  • The role of clinical experts in translational research
  • How to customize high-throughput workflows in different disease areas

The panelists will also answer your questions live during the broadcast!

The webinar will last approximately 60 minutes.


Richard Rosenquist Brandell, M.D., Ph.D.
Uppsala University
Uppsala, Sweden

Dr. Rosenquist Brandell is professor of molecular hematology in the Department of Immunology, Genetics and Pathology at Uppsala University, senior physician with the clinical genetics unit at Uppsala University Hospital, and platform director for the Clinical Sequencing Facility within the Science for Life Laboratory (SciLifeLab), Uppsala. He received his M.D. in 1996 and Ph.D. degree in 1998, becoming a specialist in clinical genetics in 2004. By employing a translational approach and utilizing cutting-edge molecular tools, his research group has made outstanding contributions to our understanding of the mechanisms behind the development of chronic lymphocytic leukemia (CLL), the most common adult leukemia. Dr. Rosenquist Brandell has built strong and competitive networks in hematology at the national, European, and international level. As head of the Cancer Genetics Section, Uppsala University, he has longstanding experience in the development, application, validation, and standardization of new cancer biomarkers and technologies, with particular focus on hematological malignancies. Recently, he established the Clinical Sequencing Facility, a collaboration between SciLifeLab, Uppsala University, and Uppsala University Hospital, which is focused on translating next-generation sequencing into clinical diagnostics.
Olli Kallioniemi, M.D., Ph.D.
Karolinska Institutet
Stockholm, Sweden

Dr. Kallioniemi received his M.D. and Ph.D. from the University of Tampere in Finland, where he also undertook his residency in laboratory medicine. He completed his postdoctoral work at the University of California, San Francisco and was appointed as faculty at the National Human Genome Research Institute at the National Institutes of Health in 1995. Together with the VTT Technical Research Centre and the University of Turku, he founded and developed the Medical Biotechnology group in Turku, Finland between 2002 and 2008. Dr. Kallioniemi was recently nominated as director of the Science for Life Laboratory, a national infrastructure for life sciences in Stockholm. He is also a professor of molecular precision medicine at the Karolinska Institutet. For the past eight years, Dr. Kallioniemi has held the position of founding director at the Institute for Molecular Medicine Finland (FIMM) and professor at the University of Helsinki. He has authored over 300 publications and is inventor or coinventor on 20 issued patents. Dr. Kallioniemi’s group is currently active in individualized systems medicine research on various cancers, with a special focus on rapid translational research to improve leukemia diagnostics and therapy.
Anna Wedell, M.D., Ph.D.
Karolinska Institutet
Stockholm, Sweden

Dr. Wedell is a professor of medical genetics in the Department of Molecular Medicine and Surgery at the Karolinska Institutet, leading a research group working with rare diseases in the area of endocrinology and metabolism. They are devoted to identifying novel disease genes, elucidating disease mechanisms in model systems, and developing innovative methods for diagnostics. Dr. Wedell has implemented clinical whole-genome sequencing for monogenic disorders at the Karolinska University Hospital, and she has discovered a number of novel monogenic diseases affecting brain metabolism, some of which have opened new avenues for treatment. She is also a senior consultant and head of the Centre for Inherited Metabolic Diseases at Karolinska University Hospital, and head of the Swedish national neonatal screening program, currently comprising 24 rare, treatable disorders. Dr. Wedell is a member of the Nobel Assembly at the Karolinska Institutet and the Nobel Committee for Physiology or Medicine, and has been a driving force behind the establishment of a clinical genomics platform at the Science for Life Laboratory in Stockholm.

Tianna Hicklin, Ph.D.
Washington, DC

Dr. Hicklin studied biology at Colorado State University for her undergraduate education before earning a Ph.D. in neuroscience from the University of Colorado Anschutz Medical Campus. Prior to joining Science/AAAS, she worked as a science writer intern for the University of Colorado’s Office of Media and Public Relations in Denver, Colorado and for Brookhaven National Laboratory’s Media and Communications Office in Upton, New York. Dr. Hicklin is currently the assistant editor for the Science/AAAS Custom Publishing Office.

  For the best experience we recommend you use Internet Explorer 6 (IE6) or higher on a Windows-based PC to view this webinar. Please ensure that you are using a computer with a stable internet connection and good bandwidth. To ensure the best possible performance of the webinar we recommend that you avoid using a dial-up connection. Note: please confirm the start time of the webinar in your time zone. A free time zone converter is available at

  Test Your System